ibritumomab

Chemical data

Formula

C24H35N5O11

Molecular weight

569.6 g/mol

IUPAC name

2-[[(2S)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid

SMILES

CC(CN(C[C@H](CC1=CC=C(C=C1)NC(=O)NC)N(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O

InChIKey

RTQWWZBSTRGEAV-PKHIMPSTSA-N

XLogP

-7.1

Polar surface area

237 Ų

H-bond donors

7

H-bond acceptors

14

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Phase 3

Molecule type

Antibody

Indications

neoplasm of mature B-cells, non-Hodgkins lymphoma, lymphoma, follicular lymphoma

via ChEMBL · EBI

💊Medication

Active ingredients

ibritumomab tiuxetan

• PHASE2COMPLETED
  Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell LymphomaMemorial Sloan Kettering Cancer Center · NCT00058422
• NACOMPLETED
  Radioimmunotherapy With 90Y Zevalin for Orbital LymphomaM.D. Anderson Cancer Center · NCT00387023
• PHASE2UNKNOWN
  Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's LymphomaMcGill University · NCT00438581
• PHASE2COMPLETED
  Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · NCT00644371
• PHASE2COMPLETED
  Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaNational Cancer Institute (NCI) · NCT00070447
• PHASE2COMPLETED
  Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)CABYC · NCT00505232

via ClinicalTrials.gov

Wikidata facts

Instance of

monoclonal antibody

Mass

569.233307

via Wikidata · CC0